Silence Therapeutics (NASDAQ: SLN) sets Craig Tooman separation package
Rhea-AI Filing Summary
Silence Therapeutics plc entered into a separation and release agreement with former executive Craig Tooman dated July 10, 2026, following his December 14, 2025 Separation Date. The company will provide $655,000 in 12 months of salary continuation, a $250,000 lump-sum severance payment, and reimbursements including $40,000 of legal fees, a $283,746.03 2025 bonus, $46,896.48 of healthcare premiums, and up to $20,000 of tax-provider fees.
Mr. Tooman’s equity awards will continue vesting for 45 days after the Separation Date, with extended post-termination option exercise periods of up to 24 months for options under the 2023 Equity Incentive Plan and 12 months for options under the 2018 Long Term Incentive Plan. Any unvested options may vest upon a change of control within 12 months after the Separation Date, conditioned on his continued compliance with the Separation Agreement, which also includes confidentiality, non-disparagement and non-solicitation covenants and a release of claims.
Positive
- None.
Negative
- None.
Filing Explained
This July 16 amendment confirms that the July 10 separation agreement supplements the December 15 report without other changes; its complete text is not included here, and the company says it intends to file it with its Form 10-Q for the quarter ended June 30, 2026.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Salary continuation: $655,000
Lump-sum severance payment: $250,000
2025 bonus payment: $283,746.03
+5 more
8 metrics
Salary continuation
$655,000
12 months following the December 14, 2025 Separation Date
Lump-sum severance payment
$250,000
Cash severance under the Separation Agreement
2025 bonus payment
$283,746.03
Bonus that would have been earned for 2025 had employment continued
Legal fees reimbursement
$40,000
For negotiation and review of the Separation Agreement
Healthcare premium reimbursement
$46,896.48
Reimbursement of healthcare premiums for Mr. Tooman
Tax provider fees
up to $20,000
Payment for fees accrued to Mr. Tooman’s tax providers
Continued vesting period
45 days
Continued vesting of options after the Separation Date
Extended exercise periods
24 months and 12 months
Post-termination exercise for 2023 Plan and 2018 Plan options, respectively
Key Terms
Separation Agreement, Separation Date, change of control, 2018 Long Term Incentive Plan, +1 more
5 terms
Separation Agreement regulatory
"the Company and Mr. Tooman entered into a separation and release agreement (the “Separation Agreement”)."
A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.
Separation Date regulatory
"effective as of December 14, 2025 (the “Separation Date”), Craig Tooman agreed by mutual consent"
change of control regulatory
"acceleration of vesting of any unvested options upon a change of control event within 12 months"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
2018 Long Term Incentive Plan financial
"the Company’s 2018 Long Term Incentive Plan (the “2018 Plan”)"
non-solicitation regulatory
"contains confidentiality, non-disparagement, non-solicitation and non-inference covenants"
A non-solicitation clause is a contractual promise that one party will not actively try to lure away another party’s employees, customers, or suppliers. For investors, it signals protection of a company’s workforce and client base after a deal or partnership—reducing the risk that key staff or revenue sources will be poached and therefore helping preserve the business’s value, predictability, and post-transaction earnings. Think of it as an agreement not to knock on a neighbor’s door to take their business or team.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive event does Silence Therapeutics (SLN) describe in this 8-K/A amendment?
The amendment describes a separation and release agreement between Silence Therapeutics and former executive Craig Tooman, detailing cash severance, salary continuation, reimbursements and equity award treatment following his December 14, 2025 separation from the company.
How much salary continuation does Craig Tooman receive from Silence Therapeutics (SLN)?
Craig Tooman will receive $655,000 in salary continuation from Silence Therapeutics, payable over 12 months following his December 14, 2025 Separation Date as part of the negotiated separation and release agreement.
What severance and bonus payments are included in the Silence Therapeutics (SLN) separation agreement?
The agreement provides a $250,000 lump-sum cash severance payment and a lump-sum bonus of $283,746.03, representing the 2025 bonus amount that Craig Tooman would have earned had he remained employed through the Separation Date.
What reimbursements will Silence Therapeutics (SLN) make to Craig Tooman?
Silence Therapeutics will reimburse $40,000 of legal fees, $46,896.48 of healthcare premiums and up to $20,000 of tax-provider fees for Craig Tooman, all in connection with his separation and the negotiation and implementation of the Separation Agreement.
How are Craig Tooman’s stock options treated under the Silence Therapeutics (SLN) Separation Agreement?
His options continue vesting for 45 days after the Separation Date, with exercise periods extended to up to 24 months for 2023 Plan options and 12 months for 2018 Plan options, plus potential accelerated vesting upon a change of control within 12 months.
Does the Silence Therapeutics (SLN) Separation Agreement include restrictive covenants?
Yes. The Separation Agreement includes confidentiality, non-disparagement, non-solicitation and related covenants, along with a release of claims by Craig Tooman in favor of Silence Therapeutics as part of the overall separation package.